Skip to main content

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes in Non-metastatic, Non-recurrent Lung and Esophageal Cancer Patients

Trial Status: Active

This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Continuous cardiac monitoring with an implanted device may help to identify cardiac changes that would remain unnoticed, and facilitate the treatment of these early cardiac changes as part of standard care.

Inclusion Criteria

  • Planned standard of care curative thoracic RT or CRT with anticipated heart V40 > 20 cc (At least 20 cc of the heart should receive a dose of 40 gray [Gy] or higher)
  • Able to follow-up at all specified standard of care time-points
  • Patients can receive treatment as part of the standard of care or in a different study
  • Receiving radiation treatment to an area close to the heart, for example gastroesophageal junction cancer, hilar lung cancer, or mainstem bronchus lung cancer
  • Any type of systemic therapy or surgery before during or after radiation is acceptable
  • Prior radiation to other areas is acceptable
  • Planned radiation doses equal or higher than 40 Gy

Exclusion Criteria

  • Metastatic disease
  • Recurrent disease
  • Patient receiving radiation prescription doses lower than 40 Gy
  • No prior radiation that included any part of the heart is acceptable
  • No thoracic re-irradiation


Mayo Clinic in Arizona
Status: ACTIVE
Contact: Carlos Enrique Vargas
Phone: 480-342-4800


I. To determine the 12-month cardiac event rate after radiation or chemo-radiation for the treatment of lung or esophageal cancer.


I. Define the spectrum of cardiac toxicity among chemoradiotherapy (CRT) patients at highest risk of cardiac toxicity.

II. Establish the timeline of cardiac toxicity development and identify early predictive findings of permanent damage.

III. Characterize the areas of the heart at highest risk for persistent cardiac damage.

IV. Identify a dose response threshold for radiotherapy (RT) damage in different areas of the heart.

V. Improve survival by alerting the cardiology team of the need for life-saving standard of care interventions.

VI. Describe medical interventions employed for the cardiac events identified in the study.


Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.

After completion of study treatment, patients are followed up at 4 weeks, 3, 9 and 12 months post RT.

Trial Phase Phase NA

Trial Type Prevention

Lead Organization
Mayo Clinic in Arizona

Principal Investigator
Carlos Enrique Vargas

  • Primary ID MC1723
  • Secondary IDs NCI-2019-07938
  • ID NCT04183218